Integra Lifesciences Holdings Corporation · NASDAQ:IART

Integra Lifesciences — Merger or Acquisition (December 2023)

12 slides from Integra Lifesciences's merger presentation, Dec 13, 2023

1. Slide 1: Acquisition of Acclarent, a Leader in ENT Surgical Interventions

   ACQUISTION OF ACCLARENT, A LEADER IN ENT SURGICAL INTERVENTIONS DECEMBER 13, 2023 Exhibit 99.2

2. Slide 2: Legal Information: Forward-Looking Statements

   Legal Information 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements,

3. Slide 3: Strategic and Accretive Approach to M&A

   International Portfolio and Channel Higher Revenue Growth, Higher Margin Growth Breadth/Depth in Care Pathway Adjacencies S T R AT E G I C F I LT E R S F I N A N C I A L F I LT E R S Accretive to Growth and/or Earnings ≥10% ROIC by Year 5     TBD Strategic and Accretive Approach to M&A Acclarent

4. Slide 4: Acquisition Overview & Strategic Rationale

   Acquisition Overview & Strategic Rationale Strategic Rationale Acclarent Business Description 2022 revenue ~$110 million, HSD Growth; gross margin in line with company average; U.S. sales only • Pioneered balloon sinus dilation to treat patients suffering from chronic sinus disease; developed first

5. Slide 5: Integra Overview

   5 1 MAYFIELD is a registered trademark of SM USA, Inc. and is used by Integra under license; ENT: Ear, Nose, and Throat Transformative leader in Neuro -access, -surgery, -monitoring Leading provider of specialty instruments solutions DuraGen®/DuraSeal® | CUSA® | MAYFIELD1 | Certas® Plus BACTISEAL® |

6. Slide 6: Codman Specialty Surgical Overview

   HAWK 6 Codman Specialty Surgical Overview Acclarent acquisition propels Integra to a leadership position in ENT 3% – 5% Market CAGR INSTRUMENTS Neuro and Specialty Instrumentation 2% – 3% Market CAGR Expansion to >$6B TAM1 • 3% – 5% Market CAGR • >$1B Revenue2 $0.2B2 Jarit® • Surgical Lighting Syste

7. Slide 7: ENT is a natural & complementary adjacency to Neurosurgery & Instruments

   7 ENT is a natural & complementary adjacency to Neurosurgery & Instruments Entering a higher growth segment where focused innovation and channels win NEURO- SURGERY INSTRUMENTSENT • Highly specialized market where focus wins • Disease states driven by patient demographics and advancements in diagnos

8. Slide 8: Attractive ENT market; why Integra & Acclarent will win

   8 1Triangulated from third-party and internal reports, numbers may not add up due to rounding 2 2022-2025 ENT Market growth CAGR 3 Other segments include Energy, RF, Cryoablation, Endoscopy / Video, and Nasal Stents Note: HSD = High single digit growth; MSD = Mid-single-digit growth; LSD = Low singl

9. Slide 9: Differentiated recent NPIs and complete suite of navigation products

   Differentiated recent NPIs and complete suite of navigation products Positioned for continued portfolio expansion in higher growth segments 9 TruDi® Navigation System is designed to provide consistent accuracy, a simple workflow, and advanced software functionality.1,2 1. ACCLARENT® ENT Navigation S

10. Slide 10: Building upon heritage and leading position in balloon technology

    Building upon heritage and leading position in balloon technology Driving category growth by creating new standards of care; supported by clinical evidence and expanding market access 10 The Acclarent AERA® Eustachian Tube Dilation (ETD) System is the first device specifically designed to dilate the

11. Slide 11: Strong business foundation to support sustainable growth

    Strong business foundation to support sustainable growth 11 Expanding Portfolio & Strong Innovation Pipeline  TruDi enhancements: including augmented reality and AI capabilities  New products to invigorate core platforms such as navigated accessories  AREA® Eustachian Tube – potential for indicat

12. Slide 12: Acclarent acquisition propels Integra to a leadership position in ENT & Neurosurgery

    Acclarent acquisition propels Integra to a leadership position in ENT & Neurosurgery ENT provides a natural and complementary adjacency to Neurosurgery 12 1 Highly complementary with neuro commercial, portfolio and R&D capabilities • Anatomical adjacency to neurosurgery, including access to brain tu

Integra LifeSciences Holdings — Merger or Acquisition (December 2023) on 6ix